SCHEMBL3421207

SCHEMBL3421207

O=C(O)CNC(=O)c1c(O)[nH]c(=O)[nH]c1=O

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 11/20 0.54
XDH P47989 16/20 0.50
APEX1 P27695 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
CASP1 P29466 1/20 0.43
BRCA1 P38398 1/20 0.43
HTT P42858 1/20 0.43
CASP7 P55210 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17941568 0.70 XDH (0.70) SLC22A12XDHKDM4EMEN1USP2
SCHEMBL10926831 0.70 SLC22A12 (1.00) SLC22A12XDHKDM4EMEN1USP2
SCHEMBL974330 0.69 PKM (0.47) APEX1KDM4EMEN1USP2ALDH1A1
SCHEMBL20929164 0.69 SMN1; SMN2 (0.51) SLC22A12XDHKDM4EMEN1USP2
SCHEMBL12777777 0.68 EGLN1 (0.48) APEX1KDM4EMEN1ALDH1A1KMT2A
SCHEMBL821620 0.68 KMT2A (0.76) KDM4EMEN1USP2ALDH1A1LMNA
SCHEMBL17629490 0.67 EGLN1 (0.50) KDM4EALDH1A1POLBHPGD
SCHEMBL4155293 0.67 EGLN1 (0.57) KDM4EMEN1USP2ALDH1A1LMNA
SCHEMBL17010244 0.67 XDH (0.77) SLC22A12XDHKDM4EMEN1USP2
SCHEMBL16700088 0.67 XDH (1.00) SLC22A12XDHKDM4EMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200157055-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2020-05-21 US claimed
EP-2037922-B9 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2017-08-23 EP claimed
EP-2037922-B1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-01-22 EP claimed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 US claimed
EP-2037922-A2 PROLYL HYDROXYLASE INHIBITORS SmithKline Beecham Corporation (US) 2009-03-25 EP claimed
WO-2007150011-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-12-27 WO claimed
US-20230227414-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2023-07-20 US disclosed
US-20230227414-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2023-07-20 US disclosed
US-20230227414-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2023-07-20 US disclosed
US-11643397-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2023-05-09 US disclosed
US-11643397-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2023-05-09 US disclosed
US-11643397-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2023-05-09 US disclosed
US-20210347740-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2021-11-11 US disclosed
US-8324208-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2012-12-04 US disclosed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 US disclosed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 US disclosed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 US disclosed
EP-2037922-A2 PROLYL HYDROXYLASE INHIBITORS SmithKline Beecham Corporation (US) 2009-03-25 EP disclosed
WO-2007150011-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-12-27 WO disclosed
WO-2007150011-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643397-B2 Prolyl hydroxylase inhibitors HIF1AN, EGLN3, EGLN2 SLC22A12 1400/4885XDH 45/4885APEX1 1164/4885
US-20210347740-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 SLC22A12 1400/4885XDH 45/4885APEX1 1164/4885
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 SLC22A12 1476/4885XDH 38/4885APEX1 1119/4885
US-20200157055-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 SLC22A12 1400/4885XDH 45/4885APEX1 1164/4885
US-20230227414-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 SLC22A12 1400/4885XDH 45/4885APEX1 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.